Gefitinib

A Clinical Study Finds Pfizer's Dacomitinib Delays The Growth of Lung Cancer Cells Better Than AstraZeneca's Iressa

Medicine & Technology Jun 06, 2017

In the last day of ASCO 2017 annual meeting on Tuesday, researchers presented the data of Dacomitinib that delayed the growth of the lung cancer longer than Gefitinib, trademarked as Iressa in newly diagnosed patients.

Gefitinib

A Clinical Study Finds Pfizer's Dacomitinib Delays The Growth of Lung Cancer Cells Better Than AstraZeneca's Iressa

Most Popular

1,029-Foot Asteroid To Make Close Approach Toward Earth at Breakneck Speed This Week

Public Health Alert: Various Ground Beef Products Produced in Late March Could Be Contaminated With E. Coli, US FSIS Warns

The Science Behind Instantized Creatine: Gains in Bulk's Game-Changing Formula

Camels Could Soon Replace Cows As Major Source of Milk; What Are the Benefits of This Dairy Product?

Tapeworm in Brain Found To Be Culprit of Man's Severe Migraines; Eating Undercooked Bacon, Not Washing Hands Properly Could Be To Blame For Infection

Recommended Stories

NASA’s Voyager 1 Resumes Sending Readable Data From Deep Space After Months of Transmitting Nonsense Responses

Small Dark Formations on the Red Planet's Surface Appear Like Spider in Photos Captured by ESA's Mars Express

Citizen Scientists Identify New Sample of Over 1,000 Hidden Asteroids in Hubble’s Archival Data

NASA Engineers Successfully Repair Voyager 1 After 5 Months of Troubleshooting 15 Billion Miles Away